Search
Generic filters

RCUS – Arcus Biosciences Inc

Not Compliant

The company’s impure earnings are more than 5% of its total revenues.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. It is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. It is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The Company’s investigational products also include etrumadenant and quemliclustat.

AAOIFI ✗

Debt ÷ Market cap (MC)0
Non-Compliant Assets ÷ MC73.78
Impure Income (incl. Interest)27.27
Impure Income%
Interest Income27.27%
Total27.27%